Showing results (2151-2160 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 7, 2019
Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparibTitto Augustine, Radhashree Maitra, Jinghang Zhang, et al.
Investigational New Drugs|January 11, 2019
Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinasesRejitha Suraj, Jasim Al-Rawi, Christopher Bradley
Investigational New Drugs|January 12, 2019
The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancersPhilippe Collery, Vijay Veena, Adhikesavan Harikrishnan, et al.
Investigational New Drugs|November 11, 2019
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG studySarah Lapointe, Warren Mason, Mary MacNeil, et al.
Investigational New Drugs|December 1, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort studyHayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, et al.
Investigational New Drugs|December 3, 2017
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancerJonathan W Goldman, Lee S Rosen, Anthony W Tolcher, et al.
Investigational New Drugs|December 24, 2017
Development of a dietary formulation of the SHetA2 chemoprevention drug for miceDoris M Benbrook, Naveena B Janakiram, Vishal Chandra, et al.
Investigational New Drugs|February 7, 2019
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trialsDylan J Martini, Yuan Liu, Julie M Shabto, et al.
Investigational New Drugs|February 7, 2019
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancerDeaglan McHugh, Mario Eisenberger, Elisabeth I Heath, et al.
Investigational New Drugs|February 2, 2019
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trialJian-Chun Duan, Zhi-Jie Wang, Lin Lin, et al.
Pageof 372